aripiprazole has been researched along with Developmental Disabilities in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, E; Deb, S; Deb, T; Farmah, BK; Roy, M; Unwin, GL | 1 |
| Adham, N; Fone, KCF; Gyertyán, I; King, MV; Kiss, B; Watson, DJG | 1 |
1 review(s) available for aripiprazole and Developmental Disabilities
| Article | Year |
|---|---|
The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Child Development Disorders, Pervasive; Developmental Disabilities; Humans; Intellectual Disability; Mental Disorders; Piperazines; Quinolones; Self-Injurious Behavior; Treatment Outcome | 2014 |
1 other study(ies) available for aripiprazole and Developmental Disabilities
| Article | Year |
|---|---|
The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Association Learning; Developmental Disabilities; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Interpersonal Relations; Locomotion; Male; Memory Disorders; Phencyclidine; Piperazines; Rats; Recognition, Psychology; Schizophrenia | 2016 |